Strata Critical Medical Reports 87.4% Revenue Growth to $67.4 Million

Strata Critical Medical, Inc. reported significant financial growth in its latest quarterly filing, with revenues reaching $67.4 million for the three months ended March 31, 2026, compared to $35.9 million in the same period last year, marking an increase of 87.4%. The company attributed this growth to a 32.4% rise in its logistics segment, which generated $47.6 million, and the introduction of clinical services following the acquisition of Keystone Perfusion Services, which contributed $19.8 million in revenue. The gross profit also saw a substantial increase, rising to $14.1 million from $7.1 million, resulting in a gross margin improvement from 19.6% to 21.0%.

In terms of profitability, Strata reported a net income of $2.2 million, a notable turnaround from a net loss of $3.5 million in the prior year. This improvement was driven by a combination of increased revenues and a reduction in operating losses from continuing operations, which decreased to $3.0 million from $5.7 million. The company’s operating expenses rose to $17.1 million, primarily due to higher selling, general, and administrative costs associated with the integration of Keystone and increased stock-based compensation.

Strategically, Strata completed the acquisition of Keystone Perfusion Services in September 2025, enhancing its clinical service offerings in organ recovery and perfusion. This acquisition is expected to bolster the company’s position in the transplant logistics market. Additionally, Strata divested its Passenger business to Joby Aero, Inc. in August 2025, a move that has been classified as a discontinued operation and is anticipated to streamline operations and focus on its core medical logistics services.

Operationally, Strata reported a total of 86,521,570 shares of common stock outstanding as of March 31, 2026. The company has also established a new asset-based revolving credit facility, providing up to $30 million in liquidity, which is expected to support its operational needs and strategic initiatives. The company’s cash and cash equivalents increased to $58.7 million, up from $31.0 million at the end of the previous fiscal year, indicating a strong liquidity position.

Looking ahead, Strata remains optimistic about its growth trajectory, driven by the increasing demand for organ transplant services and the successful integration of Keystone. The company plans to leverage its enhanced service offerings to capture a larger market share in the healthcare logistics sector, while also navigating the challenges posed by market conditions and operational complexities.